Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death (KEEPS)

This study has been completed.
Information provided by (Responsible Party):
Rachel Lampert, Yale University Identifier:
First received: December 19, 2007
Last updated: January 20, 2015
Last verified: January 2015
As an ancillary study to the KEEPS study (see Identifier: NCT00154180), the primary purpose is to measure effects of estrogen vs. placebo in menopausal women, on autonomic function and repolarization; both measured non-invasively via holter monitoring.

Menopausal Women

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effects of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death: Autonomic Function and Ventricular Repolarization Heterogeneity ( A KEEPS Ancillary Study)

Resource links provided by NLM:

Further study details as provided by Rachel Lampert, Yale University:

Primary Outcome Measures:
  • Heart rate variability [ Time Frame: 48 Months ]

Secondary Outcome Measures:
  • Repolarization parameters [ Time Frame: 48 Months ]

Enrollment: 25
Study Start Date: September 2005
Study Completion Date: December 2010
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Observing heart rate variability in placebo and active estrogen preparations
Active estogen
Observing heart rate variability in placebo and active estrogen preparations

Detailed Description:
The parent study KEEPS, will be a randomized, placebo-controlled double blinded, prospective trial with two active groups and one placebo group. Only patients enrolled in KEEPS will be invited to participate in this ancillary study.Duration of the KEEPS study will be for 4 years after randomization for each study subject, with assessment of the primary endpoint, carotid CIMT, twice at baseline, 12, 24, 36 and 48 months. Ancillary to the KEEPS study, patients will undergo holter monitoring at baseline, 24 and 48 months.Data will be analyzed after 24 and 48 months (corresponding to data analysis of the primary endpoints.) Holter monitors will be put on during the scheduled KEEPS visits, will be worn for 24 hours and will be returned the following day. Effects of estrogen on heart rate variability (HRV) and repolarization parameters will be evaluated, and also correlated with clinical, quality of life, sleep and mood information gathered through the parent study. Anticipated enrollment from the parent study at this site is 90 study subjects. This ancillary does not involve the use of drugs or investigational devices.

Ages Eligible for Study:   42 Years to 58 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Self-voluntary study subjects participating in the KEEPS parent study which is randomized, double-blind, placebo controlled.

Inclusion Criteria:

  • participant of the KEEPS parent study: Identifier NCT00154180

Exclusion Criteria:

  • non-participants of parent study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00580775

United States, Connecticut
Yale University School of Medicine / Yale New Haven Hospital
New Haven, Connecticut, United States, 208017
Sponsors and Collaborators
Yale University
Principal Investigator: Rachel Lampert, M.D. Yale University
  More Information

Responsible Party: Rachel Lampert, Associate Professor of Medicine, Yale University Identifier: NCT00580775     History of Changes
Other Study ID Numbers: 0505000069
Study First Received: December 19, 2007
Last Updated: January 20, 2015

Keywords provided by Rachel Lampert, Yale University:
Hormone Replacement Therapy
Sudden Cardiac Death

Additional relevant MeSH terms:
Death, Sudden, Cardiac
Pathologic Processes
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Death, Sudden
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017